Abstract |
In this study, we have surface-functionalized PEGylated-nanoliposomal doxorubicin (DOX) with anti- EpCAM ( epithelial cell adhesion molecule) aptamer via post-insertion of anti- EpCAM aptamer-conjugated DSPE-mPEG2000 into Caelyx® (ED-lip). The size, charge, release profile, and cytotoxicity and cellular uptake of formulation were determined. The characterization of the ED-lip demonstrated the slightly increase in size and PDI along with the decrease in zeta potential which indicated that post-insertion efficiently done. The results of flow cytometry and fluorescent microscopy have shown that ED-lip enhanced the rate of cell uptake on C26 cell line compared to Caelyx®. The ED-lip also had more cytotoxic effects than Caelyx® which indicated the efficacy of anti- EpCAM aptamer as targeting ligand. The pharmacokinetic and tissue biodistribution of formulations in mice bearing C26 tumors demonstrated that ED-lip did not affect the distribution profile of DOX compared to Caelyx® in animal model. In addition, ED-lip effectively improved the tumor accumulation of DOX and promoted survival of animals compared to Caelyx®. These results suggest that the functionalization of Caelyx® with anti- EpCAM aptamer is promising in cancer treatment and merits further investigation.
|
Authors | Mohammad Mashreghi, Parvin Zamani, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari |
Journal | Nanoscale research letters
(Nanoscale Res Lett)
Vol. 15
Issue 1
Pg. 101
(May 07 2020)
ISSN: 1931-7573 [Print] United States |
PMID | 32383027
(Publication Type: Journal Article)
|